Newly Approved Agents in HER2-Positive Metastatic Breast Cancer with Dr Mark Pegram
Dr Mark Pegram from the Stanford University School of Medicine discusses the latest clinical data on and optimal use of newly approved therapies for HER2-positive metastatic breast cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayHER2MetastaticBC21).
